With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

New York City-based Volastra Therapeutics – whose founders and scientific advisors are leading chromosomal instability researchers and experts – have in four years’ time advanced two drug candidates ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

The life sciences industry, composed of pharmaceuticals, biotechnology, and medical devices, advances healthcare to improve the quality of life for people worldwide. However, as investment in the life ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

Healthcare group purchasing organizations (GPOs) and pharmacy benefit managers (PBMs) both play a central role in today’s healthcare payment and delivery landscape. Traditionally GPOs have served ...